Aaron G.L. Fletcher

September 29, 2026

Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.

October 1, 2026

ACTU Included in Recent Healthcare Stock Movers. ACTU was listed among 12 healthcare shares that moved in Monday's after‑market session, Friday's intraday session, and Friday's pre‑market session, according to Benzinga reports. The stock is trading near its 10‑touch support level of $1.93 and has a moderate RSI of 39.1, indicating it is not yet overbought or oversold. These sessions show recent interest in the company, but no specific catalyst was highlighted.

September 30, 2026

Lantern Pharma Announces $8M Direct Offering and AI Roadmap. Lantern Pharma said it will raise up to $8 million through a registered direct offering. The company also outlined its Open‑Medicine AI platform roadmap, highlighting plans to use agentic AI for drug development. It presented these ideas on Bloomberg Television and in a SeekingAlpha slideshow. The move could support future product pipelines, while the stock’s low RSI and recent volume spike suggest increased investor interest.

October 3, 2026

Azitra Announces $3.5M Common Stock Sale Agreement and Updated Valuation. Azitra Inc. entered a sales agreement with A.G.P. to offer up to $3.5 million of common stock. The company also updated its valuation to reflect progress in its cosmetic and EGFRi rash programs. These developments were noted in a Benzinga report that listed Azitra among 12 healthcare stocks moving in Thursday’s after‑market session.

October 7, 2026

IN8bio Reports Inducement Grant Under Nasdaq Rule. IN8bio disclosed an inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate governance procedure used to attract or retain key employees. The stock is currently trading near its 52-week high, with technical indicators showing recent support rejection.

September 28, 2026

Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.